

INDEX

- aesthetic-plastic surgery 270f
 administration, estrogens 36f
 administration, progestagens 45f
 Alzheimer's disease 80, 101f
 amenorrhea, hypergonadotropic 61
 β -amyloid 101f
 anabolics 253f
 "Androcheck" 296
 androgen deficiency 293f
 androgens 30, 159f
 androstendione 30, 159f
 anti-atherogenic effect 121f
 antiresorptives 252f
 apolipoprotein E (apo E) ϵ 4 101f
 apoptosis 174
 application of HRT 75f
 atherosclerosis 82, 121f
 atrophathia climacterica 142f
 atresia, follicle 30
 atrophy, vaginal 93, 153f
 audition 141f
 autoimmune processes 62
- benefit/risk of HRT 83f, 89f
 bisphosphonates 259
 bleeding disorders 68f, 93, 166
 bone biopsy 223
 bone density 223, 252
 bone loss 218
 bone mass 212f, 218
 bone markers, biochemically 222f
 bone scintigraphy 223
 brain-stem audiometry 141
 breast cancer 187f
 BUA (Broadband Ultrasound Attenuation) 229
- calcitonin 258
 calcium 262f
 cancerogenesis 173f
 cardiovascular effects (HRT) 121f, 275f
 causal attribution 21f
 ceratoconjunctivitis sicca 137f
 cervical cancer 196
 chloromadinone acetate 46
 cholelithiasis 71
 cholecystitis 71
 climacteric
 – definition 29
 – psychological aspects 21f
 – symptoms 31, 69f
 – syndrome 31f
 – premature 29
 climacterium praecox 29
 – tardum 30
 – virile 267
 cluster analysis 26
 collagen tissue 145f
 colo-rectal cancer 198
 contra-indications (hormone replacement therapy) 70f, 168f
 – absolute 71
 – relative 71
 contraception 205f
 coronary heart disease 121f
 cyproterone acetate 46
- demographic development 15f
 dehydroepiandrosterone (DHEA) 30, 74, 131f, 159f, 267, 286, 294
 dehydroepiandrosterone sulfate (DHEA-S) 128, 131f, 159f, 267, 286, 294
 dementia 101f
 densitometry 220
 depressions 32, 103
 diabetes mellitus 80, 125, 159f
 diet 54, 74, 288
 dienogest 48
 disorders
 – metabolic 32, 82
 – urogenital 78, 153f
 – vegetative 32, 77f
 duration of treatment 69f, 84
 DXA (DEXA) 218f, 227f
 dydrogesterone 47
- empty-nest syndrome 22
 endometrial hyperplasia 90, 167
 endometrial cancer 170, 176f
 epidermal skin thickness 149
 equiline 35, 41f
 erectile dysfunction (ED) 288f, 295
 17 β -estradiol 51
 estradiol 36f
 – gel 39
 – ointment 147f
 – patch 38
 – tablets 40
 – testosterone combination 74
 – vaginal ring 40, 154
 – valerate 36f
 estriol 42f, 73
 – ointment 147f
- estrogens 33f
 – conjugated 41f, 89f
 – pharmacology 33f
 – phyto- 51f, 73, 127
 – receptor 34f, 104f
 – structural formulas 34
 estrogen-gestagene combinations 65
 estrogen replacement therapy
 – benefit/risk 83f, 89f
 – bleeding disorders 68f
 – contra-indications 70f, 168f
 – duration 69f, 84
 – indications 69, 243
 – low-dose therapy 89f, 241
 – morbidity 84
 – mortality 84
 – selection of preparation 72f
 – side effects 95f, 245
 estrone sulfate 41f
 ethinyl estradiol (EE) 47
 extragenital symptoms 135f
 eye function 137f
- family planning 205f
 fibrinogen 121f
 first-pass effect 45
 fluorides 260
 follicle-stimulating hormone (FSH) 30
 fracture risk 211f, 236f
- gender specificity 275
 gestagens 44f
 – administration 45f
 – structural formulas 43
 glaucoma 140
 glucose tolerance 159f
- haemostasis 125
 hair follicle 150
 hair loss 150
 health expectancy 280
 HDL (high density lipoproteine) 32, 123f
 hirsutism 32
 hot flushes 77
 17 α -hydroxylase deficiency 62
 hydroxyproline 225
 hyperandrogenemia, postmenopausal 125, 159f
 hyperinsulinemia 125, 160
 hyperparathyroidism 212
 hyperplasia (endometrial) 90, 167
 hypertension 121f
 hypogonadism 128, 219

- iatrogenic menopause 30, 63
immunologic causes 62
insuline resistance 125, 159f
intraocular pressure (IOP) 140
incontinence, urinary 153f
irritated bladder 153f
isoflavons 51, 74
IUD (Intra-uterine device) 207
IUS (Intra-uterine hormonal system) 207
- Kupperman-Index 78, 148
- levonorgestrel 47
Leydig cells 283, 293
LDL (low density lipoproteine) 32, 123f
life expectancy 12, 15f, 279f, 293
life style 18, 31
lignans 51, 74
lipoproteines 123f, 273f
– HDL 32, 123f
– LDL 32, 123f
– Lipoprotein (a) (LP (a)) 123f
long-term substitution 69f
loss of libido 13
lower urinary tract symptoms (LUTS) 153f, 293
luteinizing hormone (LH) 30
- mandibular joints 144
matrix patch 38
medrogestone 46
medroxyprogesterone acetate 46, 89f
menopause (definition) 29f
menopause rating scale (MRS) 23f, 78f
mucosa atrophy 79
myocardial infarction 32, 103, 121f
- neuroendocrine changes 101f
nicotine abuse 103, 213
norethisterone acetate 47
DL-norgestrel 47
Nortestosterone derivatives 47f
- obesity 125, 159f
– android (abdominal) 160
– gynecoid (ubiquitary, non-central) 160
osteoblasts 213f
osteocalcin 224
osteoclasts 213f
osteopenia 295
- osteoporosis 211f
– aetiology, pathogenesis 211f
– definition 217, 251
– male 276, 285
– prophylaxis 235f
– risk factors 211f
– therapy 251f
– type I 229, 251f
– type II 251f
ovaries
– cease to function 30
ovarian cancer 179f
ovulation inhibitor 205f
- package inserts 168
partial androgen deficiency of the ageing male (PADAM) 268, 293
partial endocrine deficiency of the ageing male (PEDAM) 268, 283
palpitations 77
pathophysiology 30f
parat hormone (PTH) 215
peak bone mass 213
perimenopause 29
pharmacology 33f
phosphatase
– alkaline 222, 224
– tartrate-resistant acid 225
photoaging 146
phytoestrogens 51f, 73, 127
pill (birth-control) 205f
pollakisuria 153f
postmenopause 29
pQCT (peripheral quantitative computer tomography) 221, 227f
premature menopause 29, 61
premenopause 29
preformed follicles 31
progesterone 44f
– derivatives 45f
procollagen/propeptide 225
prostate cancer 296
pyridinoline-crosslinks 225
- raloxifene 127, 242, 258
reservoir patch 38
rheumatoid arthritis 143f
risk factors, cardiovascular 123f
risk factors, osteoporosis 211f
- Schirmer's test 139
self esteem 23f
selective estrogen-receptor modulators (SERM) 73, 127, 242, 258
- senium 29, 30
sexual hormone-binding globuline (SHBG) 48, 129, 159f
sexuality 82, 288
shifting role 22
skin 79, 145f
– ageing 145f
– atrophy 145f
– thickness measure (Osteoson®) 230f
smoking 31, 62, 281
soy 51f, 74
SOS (speed of sound) 229
sphincter failure 153f
sterilization 210
stress incontinence 153f
- tamoxifene 127, 242
testosterone 30, 128f
– level 297
– rhythm 297
– supplementation 286, 297
therapy adherence 76f
thrombosis 121f
thyroid gland 30
tibolone 48, 73, 127, 242, 258
t-score 218f, 251
triglycerides 123f
Turner-syndrome 62, 220
type I-osteoporosis 251f
type II-osteoporosis 251f
- ultrasound 227f
– reflection method 228
– transmission method 229
urethral syndrome 153f
urethral pressure 153f
urge incontinence 153f
urogenital atrophy 32, 153f
urogenital disorders 78, 153f
uterine sarcoma 197
- vaginal prolaps 153f
vaginal carcinoma 197
vaginal ring (with estradiol) 40, 154
vasomotoric disorders 32, 91f
vegetative disorders 32, 77f
vertebral bone 212f
vitamin D 215, 262f
– deficiency 215
– receptor 213
- weight problems 167
z-score 221, 251

Editor:
Franz H. Fischl



MENOPAUSE ***ANDROPAUSE***

Hormone replacement therapy through the ages
New cognition and therapy concepts

<http://www.kup.at/cd-buch/8-inhalt.html>

Krause & Pachernegg GmbH
VERLAG für MEDIZIN und WIRTSCHAFT